Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

<i>Background and Objectives:</i> Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectiveness and safet...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-07-01
Colecção:	Medicina
Assuntos:	alirocumab evolocumab inclisiran hypercholesterolemia proprotein convertase subtilisin/kexin type 9 inhibitors
Acesso em linha:	https://www.mdpi.com/1648-9144/60/7/1124
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!